Dry Eye Syndrome
暂无分享,去创建一个
[1] L. Liang,et al. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. , 2004, Cytokine.
[2] S. Kelsen,et al. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. , 1999, The Journal of allergy and clinical immunology.
[3] K. Rajagopalan,et al. The Economic Burden of Dry Eye: A Conceptual Framework and Preliminary Assessment , 2004, Cornea.
[4] R. Yee,et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. , 1998, Advances in Experimental Medicine and Biology.
[5] K. Tsubota,et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome , 1998, The British journal of ophthalmology.
[6] De-Quan Li,et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.
[7] S. Pflugfelder,et al. Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. , 1994, Investigative ophthalmology & visual science.
[8] C. Blehm,et al. Computer vision syndrome: a review. , 2005, Survey of ophthalmology.
[9] Maciej Kaczmarski,et al. Elevated tear fluid levels of MIP-1alpha in patients with cystic fibrosis. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[10] Yolanda Diebold,et al. Impression cytology of the ocular surface: a review. , 2004, Experimental eye research.
[11] M. Calonge. The treatment of dry eye. , 2001, Survey of ophthalmology.
[12] R. Tripathi,et al. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. , 1992, Lens and eye toxicity research.
[13] Christopher Snyder,et al. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. , 2005, Investigative ophthalmology & visual science.
[14] K. Gündüz,et al. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome , 1994, Acta ophthalmologica.
[15] P. Weber,et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. , 1989, The New England journal of medicine.
[16] C. Baudouin,et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.
[17] L. Sobrin,et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. , 2000, Investigative ophthalmology & visual science.
[18] A. Lenton,et al. Management of Filamentary Keratitis Associated with Aqueous-Deficient Dry Eye , 2003, Optometry and vision science : official publication of the American Academy of Optometry.
[19] L. Sobrin,et al. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. , 1999, Investigative ophthalmology & visual science.
[20] R. Noecker,et al. Effects of common ophthalmic preservatives on ocular health , 2001, Advances in therapy.
[21] Tsutomu Takeuchi,et al. Conjunctival Epithelium Expression of HLA-DR in Dry Eye Patients , 1998, Ophthalmologica.
[22] Lee Stern,et al. Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.
[23] Rebecca Diller,et al. A case report and review of filamentary keratitis. , 2005, Optometry.
[24] J. Craig,et al. Tear lipid layer structure and stability following expression of the meibomian glands. , 1995, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.
[25] T. Mclaughlin,et al. Prevalence of treated dry eye disease in a managed care population. , 2001, Clinical therapeutics.
[26] J. Guest,et al. The Annual Cost of Dry Eye Syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom Among Patients Managed by Ophthalmologists , 2006, Ophthalmic epidemiology.
[27] De-Quan Li,et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.
[28] P. Aragona,et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients , 2005, Eye.
[29] G. Chomette,et al. Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features , 1988, Histopathology.
[30] G. Foulks,et al. The correlation between the tear film lipid layer and dry eye disease. , 2007, Survey of ophthalmology.
[31] S. Pflugfelder,et al. Assessing the severity of keratitis sicca with videokeratoscopic indices. , 2002, Ophthalmology.
[32] Murat Dogru,et al. Laboratory findings in tear fluid analysis. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[33] J. Ubels,et al. Retinol secretion by the lacrimal gland. , 1986, Investigative ophthalmology & visual science.
[34] Ji,et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium , 2000, American journal of ophthalmology.
[35] Christophe Baudouin,et al. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[36] C. Foster,et al. Ocular rosacea: patient characteristics and follow-up. , 1997, Ophthalmology.
[37] M. Fini,et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.
[38] H. Sheardown,et al. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. , 2004, Experimental eye research.
[39] S. Pflugfelder,et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.
[40] S. Pflugfelder,et al. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.
[41] R. Latkany. Dry eyes: etiology and management , 2008, Current opinion in ophthalmology.
[42] S. Barabino,et al. Distribution of Conjunctival HLA-DR Expression and the Pathogenesis of Damage in Early Dry Eyes , 2005, Cornea.
[43] S. Tuft,et al. Medical management of dry eye disease. , 2008, Developments in ophthalmology.
[44] K. Frei,et al. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. , 1999, Journal of cell science.
[45] Stanley B. Cohen,et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.
[46] H. Taylor,et al. The epidemiology of dry eye in Melbourne, Australia , 1998 .
[47] B. Reis,et al. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. , 2000, Ophthalmology.
[48] Yansui Li,et al. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. , 2001, American journal of physiology. Cell physiology.
[49] Carolyn G. Begley,et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[50] De-Quan Li,et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. , 2006, Investigative ophthalmology & visual science.
[51] Julie M Albietz,et al. Chronic dry eye and regression after laser in situ keratomileusis for myopia , 2004, Journal of cataract and refractive surgery.
[52] J. Gustafsson,et al. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. , 2000, Biochemical and biophysical research communications.
[53] Stefano Barabino,et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. , 2008, Archives of ophthalmology.
[54] A. Solomon,et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. , 2001, Investigative ophthalmology & visual science.
[55] J. P. Gilbard. The diagnosis and management of dry eyes. , 2005, Otolaryngologic clinics of North America.
[56] A. Solomon,et al. The Diagnosis and Management of Dry Eye: A Twenty-five–Year Review , 2000, Cornea.
[57] J. D. Nelson,et al. Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca. , 1994, Advances in experimental medicine and biology.
[58] M. Yaron,et al. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. , 1998, Ophthalmology.
[59] Stacy A. Voils,et al. Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases , 2005, The Annals of pharmacotherapy.
[60] De-Quan Li,et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. , 2007, Investigative ophthalmology & visual science.
[61] J. Buring,et al. Prevalence of dry eye syndrome among US women. , 2003, American journal of ophthalmology.
[62] Christophe Baudouin,et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[63] R. Gibson,et al. Dietary polyunsaturated fatty acids and inflammatory mediator production. , 2000, The American journal of clinical nutrition.
[64] J. Hirsch. Considerations in the pharmacoeconomics of dry eye. , 2003, Managed care.
[65] A. Solomon,et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. , 2001, American journal of ophthalmology.
[66] E. Cohen,et al. Tarsorrhaphy: Clinical Experience From a Cornea Practice , 2001, Cornea.
[67] D. Buxton,et al. Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. , 1987, Archives of ophthalmology.
[68] B. Munoz,et al. Prevalence of dry eye among the elderly. , 1997, American journal of ophthalmology.
[69] K. Tsubota,et al. Abnormal protein profiles in tears with dry eye syndrome. , 2003, American journal of ophthalmology.
[70] S. Pflugfelder,et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. , 2005, Ophthalmology.
[71] G. Milazzo,et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye , 2002, The British journal of ophthalmology.
[72] G. Geerling,et al. Autologous serum eye drops for ocular surface disorders , 2004, British Journal of Ophthalmology.
[73] R. Nussenblatt,et al. Inhibition of Inflammatory Cytokine Production in Human Corneal Cells by Dexamethasone, but Not Cyclosporin , 2006, Cornea.
[74] K. Bjerrum,et al. Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years. , 2009, Acta ophthalmologica Scandinavica.
[75] M. O’connell,et al. Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca , 1993, Cornea.
[76] De-Quan Li,et al. Strain-Related Cytokine Profiles on the Murine Ocular Surface in Response to Desiccating Stress , 2007, Cornea.
[77] I. Gipson,et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.
[78] B. Reis,et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. , 2000, Ophthalmology (Rochester, Minn.).
[79] Jian-ping Gao,et al. Desiccating Stress Induces T Cell-Mediated Sjögren’s Syndrome-Like Lacrimal Keratoconjunctivitis1 , 2006, The Journal of Immunology.
[80] A J Bron,et al. Functional aspects of the tear film lipid layer. , 2004, Experimental eye research.
[81] N. Kasetsuwan,et al. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study , 2006, British Journal of Ophthalmology.
[82] D. Korb,et al. Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction. , 1994, Advances in experimental medicine and biology.
[83] G. Kymionis,et al. Treatment of chronic dry eye: focus on cyclosporine , 2008, Clinical ophthalmology.
[84] G. Geerling,et al. Flow chart on surgical approaches to dry eye. , 2008, Developments in ophthalmology.
[85] J. Kremer. n-3 fatty acid supplements in rheumatoid arthritis. , 2000, The American journal of clinical nutrition.
[86] James E. Evans,et al. Androgen Deficiency, Meibomian Gland Dysfunction, and Evaporative Dry Eye , 2002, Annals of the New York Academy of Sciences.
[87] J. Chodosh,et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.
[88] H. Brewitt,et al. Dry eye disease: the scale of the problem. , 2001, Survey of ophthalmology.
[89] R. Montés-Micó,et al. Role of the tear film in the optical quality of the human eye , 2007, Journal of cataract and refractive surgery.
[90] J. Gustafsson,et al. Glucocorticoid Effects on NF-κB Binding in the Transcription of the ICAM-1 Gene☆ , 2000 .
[91] M. Dana,et al. Economic and quality of life impact of dry eye symptoms in women with Sjögren's syndrome. , 2000, Advances in experimental medicine and biology.
[92] W. Feuer,et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. , 1999, Ophthalmology.
[93] Gerd Geerling,et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[94] M. Lemp. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.
[95] W. Wee,et al. Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye , 2007, Korean journal of ophthalmology : KJO.
[96] J. Buring,et al. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. , 2009, Archives of ophthalmology.
[97] K. Tsubota,et al. Autologous Serum Eye Drops for the Treatment of Dry Eye Diseases , 2008, Cornea.
[98] S. Matsuda,et al. Mechanisms of action of cyclosporine. , 2000, Immunopharmacology.
[99] L. T. Jones. The lacrimal secretory system and its treatment. , 1966, Journal of the All-India Ophthalmological Society.
[100] R. Beuerman,et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. , 1998, Cornea.
[101] K. Tsubota,et al. Meibomian gland dysfunction in patients with Sjögren syndrome. , 1998, Ophthalmology.
[102] L. Cleland,et al. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. , 1997, Seminars in arthritis and rheumatism.
[103] K. Yoon,et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. , 2007, Investigative ophthalmology & visual science.
[104] W. Feuer,et al. Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion , 2000, Cornea.
[105] J. Baum,et al. Basic tear flow. Does it exist? , 1980, Ophthalmology.
[106] D. Dartt. Control of mucin production by ocular surface epithelial cells. , 2004, Experimental eye research.
[107] G. Ravera,et al. Systemic Linoleic and &ggr;-Linolenic Acid Therapy in Dry Eye Syndrome With an Inflammatory Component , 2003, Cornea.
[108] De-Quan Li,et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. , 2006, Experimental eye research.
[109] S. Chee,et al. Immunosuppressive therapy for ocular diseases , 2008, Current opinion in ophthalmology.
[110] K. Tsubota,et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. , 1999, Investigative ophthalmology & visual science.
[111] P. Asbell. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion* , 2006, Current medical research and opinion.
[112] J. Ubels,et al. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. , 1991, Current eye research.
[113] De-Quan Li,et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. , 2004, Investigative ophthalmology & visual science.
[114] J. Buring,et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. , 2005, The American journal of clinical nutrition.
[115] R. Farris,et al. Tear osmolarity--a new gold standard? , 1994, Advances in experimental medicine and biology.
[116] J. Ubels,et al. Artificial Tear Composition and Promotion of Recovery of the Damaged Corneal Epithelium , 1993, Cornea.
[117] W. Feuer,et al. Conjunctival cytologic features of primary Sjögren's syndrome. , 1990, Ophthalmology.
[118] R. Klein,et al. Prevalence of and risk factors for dry eye syndrome. , 2000, Archives of ophthalmology.
[119] J. Chodosh,et al. Oral Tetracyclines for Ocular Rosacea: An Evidence-Based Review of the Literature , 2004, Cornea.
[120] K. Tsubota,et al. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. , 1999, Cornea.
[121] R. Herrero-Vanrell,et al. [Autologous serum in the treatment of dry eye syndrome. Technological aspects]. , 2008, Archivos de la Sociedad Española de Oftalmología.
[122] D. Thompson,et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. , 2002, Investigative ophthalmology & visual science.
[123] H. Kim,et al. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells , 2006 .
[124] P Troiano,et al. Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency , 2004, Occupational and Environmental Medicine.
[125] C. Creuzot-Garcher,et al. CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/ T(H)2 in ocular surface disorders. , 2005, The Journal of allergy and clinical immunology.
[126] Henry D Perry,et al. Dry eye disease: pathophysiology, classification, and diagnosis. , 2008, The American journal of managed care.